Initial TPS serum level as an indicator of relapse and survival in colorectal cancer

Moshe Mishaeli, Baruch Klein, Evgeny Sadikov, Ishak Bayer, Rumelia Koren, Rivka Gal, Erika Rakowsky, Israel Levin, Batya Kfir, Jakob Schachter, Tirza Klein

Research output: Contribution to journalArticlepeer-review


Background. Tissue polypeptide specific antigen (TPS) measures a soluble fragment of cytokeratine 18 and may be regarded as a proliferative marker. Materials and Methods. TPS was measured in 173 consecutive patients with colorectal cancer. Median follow up time was 36 months. Of 137 evaluable patients 39 developed metastases (P.D.) and 98 remained with no evidence of disease (N.E.D.). Results. Initial TPS levels were elevated in 75% of P.D. patients compared to 32% of N.E.D. patients (p < 0.001), CEA levels were elevated in 26% of P.D. patients compared to 2% of N.E.D. In Dukes' B2 92.8% of P.D. patients had elevated initial TPS compared to 35.5% of N.E.D. patients (p < 0.001) and CEA was elevated in 33.3% of the P.D. patients compared to 1.3% of N.E.D. patients (p < 0.001). Survival and disease free survival were significantly shorter for patients with initial high TPS level. TPS was more sensitive than CEA in predicting relapse. Conclusions. These preliminary data suggest that TPS may be a prognostic factor for relapse and may help to allocate Dukes' B2 patients for adjuvant chemotherapy.

Original languageEnglish
Pages (from-to)2101-2105
Number of pages5
JournalAnticancer Research
Issue number3 B
StatePublished - May 1998
Externally publishedYes


  • CEA
  • Colorectal cancer
  • Relapse
  • TPS


Dive into the research topics of 'Initial TPS serum level as an indicator of relapse and survival in colorectal cancer'. Together they form a unique fingerprint.

Cite this